User profiles for Aymaan Zaheer
 | Aymaan ZaheerImmunobiology Lab, THSTI Verified email at thsti.res.in Cited by 159 |
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B. 1.617. 2) variant surge in India: a test-negative, case-control study and …
Background SARS-CoV-2 variants of concern (VOCs) have threatened COVID-19 vaccine
effectiveness. We aimed to assess the effectiveness of the ChAdOx1 nCoV-19 vaccine, …
effectiveness. We aimed to assess the effectiveness of the ChAdOx1 nCoV-19 vaccine, …
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo …
Background After establishing safety and immunogenicity of Biological-E’s CORBEVAX™
vaccine in adult population (18–80 years) in Phase 1–3 studies, vaccine is further tested in …
vaccine in adult population (18–80 years) in Phase 1–3 studies, vaccine is further tested in …
[HTML][HTML] Proinflammatory innate cytokines and distinct metabolomic signatures shape the T cell response in active COVID-19
The underlying factors contributing to the evolution of SARS-CoV-2-specific T cell responses
during COVID-19 infection remain unidentified. To address this, we characterized innate …
during COVID-19 infection remain unidentified. To address this, we characterized innate …
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™(ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind …
Optimum formulation of Biological-E’s protein subunit CORBEVAX™ vaccine was selected
in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. …
in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. …
Immunogenic superiority and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™(ChAdOx1 nCoV-19) vaccine studied in a phase III, single …
Background Optimum formulation of Biological E’s CORBEVAX™ vaccine that contains
protein sub unit of Receptor Binding Domain (RBD) from the spike protein of SARS-COV-2 …
protein sub unit of Receptor Binding Domain (RBD) from the spike protein of SARS-COV-2 …
[HTML][HTML] A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
Measuring SARS-CoV-2-specific T cell responses is crucial to understanding an individual’s
immunity to COVID-19. However, high inter- and intra-assay variability make it difficult to …
immunity to COVID-19. However, high inter- and intra-assay variability make it difficult to …
Cellular immune responses are preserved and may contribute to Chadox1 ChAdOx1 nCoV-19 vaccine effectiveness against infection due to SARS-CoV-2 B· 1· 617· 2 …
Background: The emergence of SARS-CoV-2 variants of concern (VoC) has threatened the
effectiveness of vaccination due to decreased neutralisation ability of the vaccine generated …
effectiveness of vaccination due to decreased neutralisation ability of the vaccine generated …
Advances in limitations and opportunities of clean biofuel production to promote decarbonization
AS Khawaja, MA Zaheer, A Ahmad, AA Mirani, Z Ali - Fuel, 2023 - Elsevier
Factors such as higher fuel prices, limited and geologically posited fossil fuel resources
along with the impact of fossil fuels on global warming are highly unsustainable for growing …
along with the impact of fossil fuels on global warming are highly unsustainable for growing …
[PDF][PDF] Innate immune response and distinct metabolomic signatures together drive and shape the SARS-CoV-2-specific T cell response during COVID-19
The underlying factors contributing to the evolution of SARS-CoV-2-specific T cell response
during COVID-19 infection remain unidentified. To address this, we characterized innate and …
during COVID-19 infection remain unidentified. To address this, we characterized innate and …
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either …
Background Vaccines developed against Covid-19 infection were effective in controlling
symptomatic infections and hospitalizations. However, waning immunity was reported within 6 …
symptomatic infections and hospitalizations. However, waning immunity was reported within 6 …